ReviewRespiratory research2005
Molecular mechanisms of severe acute respiratory syndrome (SARS).
Review in Respiratory research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses.Respiratory research · 2020Pooled it
- A Narrative Review on the Pandemic Zoonotic RNA Virus Infections Occurred During the Last 25 Years.Journal of epidemiology and global health · 2024Review
- Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Review
- Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors.Communications biology · 2023Article
- Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor.Journal of molecular biology · 2022Article
- Respiratory illness virus infections with special emphasis on COVID-19.European journal of medical research · 2022Review
- Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain.Communications biology · 2022Article
- Current landscape of gene-editing technology in biomedicine: Applications, advantages, challenges, and perspectives.MedComm · 2022Review
- Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022Review
- Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor.Communications biology · 2022Article
- Review
- Programmable Biosensors Based on RNA-Guided CRISPR/Cas Endonuclease.Biological procedures online · 2022Review
- From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines.Nano-micro letters · 2022Review
- In Sickness and in Health: Narratives on Epidemics as Tools for Science Teaching in Secondary Schools.Science & education · 2022Article
- Latest Insights on the Diagnostic Approaches and Treatment Strategies of COVID-19.Intervirology · 2022Review
- A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses.Molecules (Basel, Switzerland) · 2021Review
- Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.Advanced therapeutics · 2021Review
- An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks.Pathogens (Basel, Switzerland) · 2021Review
- COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts.Immunological reviews · 2021Review
- Human cell receptors: potential drug targets to combat COVID-19.Amino acids · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome (SARS) is a new infectious disease caused by a novel coronavirus that leads to deleterious pulmonary pathological features. Due to its high morbidity and mortality and widespread occurrence, SARS has evolved as an important respiratory disease which may be encountered everywhere in the world. The virus was identified as the causative agent of SARS due to the efforts of a WHO-led laboratory network. The potential mutability of the SARS-CoV genome may lead to new SARS outbreaks and several regions of the viral genomes open reading frames have been identified which may contribute to the severe virulence of the virus. With regard to the pathogenesis of SARS, several mechanisms involving both direct effects on target cells and indirect effects via the immune system may exist. Vaccination would offer the most attractive approach to prevent new epidemics of SARS, but the development of vaccines is difficult due to missing data on the role of immune system-virus interactions and the potential mutability of the virus. Even in a situation of no new infections, SARS remains a major health hazard, as new epidemics may arise. Therefore, further experimental and clinical research is required to control the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.